{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:36:37Z","timestamp":1786451797047,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    MicroRNAs (miRNAs) are central post-transcriptional regulators that shape oncogenic and tumor-suppressive networks through RNA-induced silencing complex (RISC)\u2013mediated repression of target mRNAs. Among these, hsa-miR-107\u2014a member of the miR-16 family encoded within an intron of the\n                    <jats:italic>PANK1<\/jats:italic>\n                    gene\u2014has emerged as a particularly paradoxical regulator in cancer. Accumulating evidence indicates that miR-107 cannot be classified as a single-function miRNA; instead, it behaves as a context-dependent \u201cmolecular switch\u201d whose impact is dictated by tissue-specific target availability, tumor stage, and the surrounding regulatory landscape. This review synthesizes mechanistic and translational data explaining how miR-107 exerts opposing roles as both a tumor suppressor and an oncomiR. In tumor-suppressive contexts, miR-107 integrates into stress-response circuitry via a p53\/\n                    <jats:italic>PANK1<\/jats:italic>\n                    \/miR-107 axis, repressing HIF-1\u03b2, impairing HIF-1 complex formation, and reducing VEGF-driven angiogenesis. miR-107 also restricts proliferation and invasion by targeting cell-cycle kinases (e.g.,\n                    <jats:italic>CDK6<\/jats:italic>\n                    and\n                    <jats:italic>CDK8<\/jats:italic>\n                    ), suppressing NOTCH2 signaling in glioma, and attenuating pro-survival PI3K\/AKT signaling indirectly in NSCLC through\n                    <jats:italic>BDNF<\/jats:italic>\n                    repression. Conversely, in aggressive cancers, miR-107 promotes malignancy through \u201cmeta-oncogenic\u201d disruption of global miRNA biogenesis by targeting\n                    <jats:italic>DICER1<\/jats:italic>\n                    , enabling EMT programs via loss of miR-200 family activity. It also activates PI3K\/AKT signaling through direct repression of\n                    <jats:italic>PTEN<\/jats:italic>\n                    (notably in bladder cancer) and enhances metastatic behavior in colorectal cancer by co-silencing metastasis suppressors such as DAPK and KLF4. A distinctive layer of complexity is added by miR-107-mediated miRNA\u2013miRNA interaction, exemplified by direct destabilization of the tumor-suppressive let-7 family in advanced breast cancer. Therefore, the review highlights higher-order regulation by lncRNA competing endogenous RNA (ceRNA) \u201csponges\u201d that sequester miR-107 (e.g., LINC00662, UASR1, H19, MFI2-AS1), thereby rewiring downstream oncogenic pathways. We discuss emerging clinical implications of miR-107 as a biomarker and as a therapeutic lever for reversing multidrug resistance, while outlining key challenges for safe, context-aware miRNA-based interventions.\n                  <\/jats:p>","DOI":"10.1038\/s41417-026-01042-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:33:02Z","timestamp":1780392782000},"page":"888-896","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The paradox of miR-107 in oncology: dual roles as a tumor suppressor and oncomiR"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2203-4650","authenticated-orcid":false,"given":"Mamdouh A.","family":"Ragab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevine","family":"Fathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin M.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7934-5030","authenticated-orcid":false,"given":"Sally A.","family":"Fahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1042_CR1","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3390\/biom15101393","volume":"15","author":"S Ding","year":"2025","unstructured":"Ding S, Wang P. The life of MicroRNAs: biogenesis, function and decay in cancer. Biomolecules. 2025;15:1393.","journal-title":"Biomolecules"},{"key":"1042_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.581007","volume":"10","author":"T Annese","year":"2020","unstructured":"Annese T, Tamma R, De Giorgis M, Ribatti D. microRNAs biogenesis, functions and role in tumor angiogenesis. Front Oncol. 2020;10:581007.","journal-title":"Front Oncol"},{"key":"1042_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/ijms14010480","volume":"14","author":"L Sacco","year":"2012","unstructured":"Sacco L, Masotti A. Recent insights and novel bioinformatics tools to understand the role of microRNAs binding to 5\u2019 untranslated region. Int J Mol Sci. 2012;14:480\u201395.","journal-title":"Int J Mol Sci"},{"key":"1042_CR4","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1101\/gr.139758.112","volume":"23","author":"J Hausser","year":"2013","unstructured":"Hausser J, Syed AP, Bilen B, Zavolan M. Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation. Genome Res. 2013;23:604\u201315.","journal-title":"Genome Res"},{"key":"1042_CR5","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.3389\/fimmu.2018.02491","volume":"9","author":"N Yang","year":"2018","unstructured":"Yang N, Zhu S, Lv X, Qiao Y, Liu YJ, Chen J. MicroRNAs: pleiotropic regulators in the tumor microenvironment. Front Immunol. 2018;9:2491.","journal-title":"Front Immunol"},{"key":"1042_CR6","doi-asserted-by":"crossref","unstructured":"Tucci P. The role of microRNAs in cancer: functions, biomarkers and therapeutics. Cancers. 2022;14:872.","DOI":"10.3390\/cancers14040872"},{"key":"1042_CR7","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. 2018;9:402.","journal-title":"Front Endocrinol"},{"key":"1042_CR8","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1093\/nar\/gks026","volume":"40","author":"MA Havens","year":"2012","unstructured":"Havens MA, Reich AA, Duelli DM, Hastings ML. Biogenesis of mammalian microRNAs by a non-canonical processing pathway. Nucleic Acids Res. 2012;40:4626\u201340.","journal-title":"Nucleic Acids Res"},{"key":"1042_CR9","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.2147\/CMAR.S198886","volume":"11","author":"W Ren","year":"2019","unstructured":"Ren W, Zhang X, Li W, Feng Q, Feng H, Tong Y, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res. 2019;11:4023\u201340.","journal-title":"Cancer Manag Res"},{"key":"1042_CR10","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1073\/pnas.0911082107","volume":"107","author":"M Yamakuchi","year":"2010","unstructured":"Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, et al. P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA. 2010;107:6334\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1042_CR11","doi-asserted-by":"publisher","first-page":"4113","DOI":"10.2147\/OTT.S151236","volume":"11","author":"Z Luo","year":"2018","unstructured":"Luo Z, Zheng Y, Zhang W. Pleiotropic functions of miR107 in cancer networks. Onco Targets Ther. 2018;11:4113\u201324.","journal-title":"Onco Targets Ther"},{"key":"1042_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3892\/ijo.2016.3628","volume":"49","author":"H Xia","year":"2016","unstructured":"Xia H, Li Y, Lv X. MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K\/AKT pathway in human non-small lung cancer. Int J Oncol. 2016;49:1325\u201333.","journal-title":"Int J Oncol"},{"key":"1042_CR13","first-page":"8616","volume":"22","author":"QF Yu","year":"2018","unstructured":"Yu QF, Liu P, Li ZY, Zhang CF, Chen SQ, Li ZH, et al. MiR-103\/107 induces tumorigenicity in bladder cancer cell by suppressing PTEN. Eur Rev Med Pharmacol Sci. 2018;22:8616\u201323.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1042_CR14","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1158\/0008-5472.CAN-12-0667","volume":"72","author":"HY Chen","year":"2012","unstructured":"Chen HY, Lin YM, Chung HC, Lang YD, Lin CJ, Huang J, et al. miR-103\/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 2012;72:3631\u201341.","journal-title":"Cancer Res"},{"key":"1042_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s11658-019-0155-z","volume":"24","author":"Y Fu","year":"2019","unstructured":"Fu Y, Lin L, Xia L. MiR-107 function as a tumor suppressor gene in colorectal cancer by targeting transferrin receptor 1. Cell Mol Biol Lett. 2019;24:31.","journal-title":"Cell Mol Biol Lett"},{"key":"1042_CR16","first-page":"32","volume":"7","author":"XY Li","year":"2014","unstructured":"Li XY, Luo QF, Wei CK, Li DF, Li J, Fang L. MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer. Int J Clin Exp Med. 2014;7:32\u201340.","journal-title":"Int J Clin Exp Med"},{"key":"1042_CR17","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1172\/JCI45390","volume":"121","author":"PS Chen","year":"2011","unstructured":"Chen PS, Su JL, Cha ST, Tarn WY, Wang MY, Hsu HC, et al. miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. J Clin Investig. 2011;121:3442\u201355.","journal-title":"J Clin Investig"},{"key":"1042_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/jmcb\/mjq040","volume":"3","author":"Z Feng","year":"2011","unstructured":"Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol. 2011;3:44\u201350.","journal-title":"J Mol Cell Biol"},{"key":"1042_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s12032-011-9823-1","volume":"29","author":"L Feng","year":"2012","unstructured":"Feng L, Xie Y, Zhang H, Wu Y. miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2012;29:856\u201363.","journal-title":"Med Oncol"},{"key":"1042_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/nar\/gkq796","volume":"39","author":"L Bohlig","year":"2011","unstructured":"Bohlig L, Friedrich M, Engeland K. p53 activates the PANK1\/miRNA-107 gene leading to downregulation of CDK6 and p130 cell cycle proteins. Nucleic Acids Res. 2011;39:440\u201353.","journal-title":"Nucleic Acids Res"},{"key":"1042_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11060-012-1037-7","volume":"112","author":"L Chen","year":"2013","unstructured":"Chen L, Chen XR, Zhang R, Li P, Liu Y, Yan K, et al. MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. J Neurooncol. 2013;112:59\u201366.","journal-title":"J Neurooncol"},{"key":"1042_CR22","doi-asserted-by":"crossref","unstructured":"Liu J, Sauer MA, Hussein SG, Yang J, Tenen DG, Chai L. SALL4 and microRNA: the role of Let-7. Genes. 2021;12:1301.","DOI":"10.3390\/genes12091301"},{"key":"1042_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3892\/ijo.2023.5478","volume":"62","author":"Z Xie","year":"2023","unstructured":"Xie Z, Xu X, Cao W, He L, Kou C, He J, et al. Perspectives on miRNAs directly targeting BDNF for cancer diagnosis and treatment (Review). Int J Oncol. 2023;62:30.","journal-title":"Int J Oncol"},{"key":"1042_CR24","first-page":"1958","volume":"19","author":"P Cai","year":"2020","unstructured":"Cai P, Li J, Chen G, Peng B, Yu L, Zhao B, et al. MicroRNA-107 may regulate lung cancer cell proliferation and apoptosis by targeting TP53 regulated inhibitor of apoptosis 1. Oncol Lett. 2020;19:1958\u201366.","journal-title":"Oncol Lett"},{"key":"1042_CR25","doi-asserted-by":"publisher","first-page":"12046","DOI":"10.18632\/aging.202908","volume":"13","author":"HA Chen","year":"2021","unstructured":"Chen HA, Li CC, Lin YJ, Wang TF, Chen MC, Su YH, et al. Hsa-miR-107 regulates chemosensitivity and inhibits tumor growth in hepatocellular carcinoma cells. Aging. 2021;13:12046\u201357.","journal-title":"Aging"},{"key":"1042_CR26","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1111\/j.1582-4934.2010.01194.x","volume":"15","author":"X Li","year":"2011","unstructured":"Li X, Zhang Y, Shi Y, Dong G, Liang J, Han Y, et al. MicroRNA-107, an oncogene microRNA that regulates tumour invasion and metastasis by targeting DICER1 in gastric cancer. J Cell Mol Med. 2011;15:1887\u201395.","journal-title":"J Cell Mol Med"},{"key":"1042_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.3390\/cancers7020598","volume":"7","author":"RU Takahashi","year":"2015","unstructured":"Takahashi RU, Miyazaki H, Ochiya T. The roles of MicroRNAs in breast cancer. Cancers. 2015;7:598\u2013616.","journal-title":"Cancers"},{"key":"1042_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/1244067","volume":"2023","author":"H Pan","year":"2023","unstructured":"Pan H, Peng H, Dai Y, Han B, Yang G, Jiang N, et al. Effects of miR-107 on breast cancer cell growth and death via regulation of the PTEN\/AKT signaling pathway. J Oncol. 2023;2023:1244067.","journal-title":"J Oncol"},{"key":"1042_CR29","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1002\/cam4.2396","volume":"8","author":"L Wang","year":"2019","unstructured":"Wang L, Li K, Wang C, Shi X, Yang H. miR-107 regulates growth and metastasis of gastric cancer cells via activation of the PI3K-AKT signaling pathway by down-regulating FAT4. Cancer Med. 2019;8:5264\u201373.","journal-title":"Cancer Med"},{"key":"1042_CR30","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3727\/096504016X14803476672380","volume":"25","author":"F Liu","year":"2017","unstructured":"Liu F, Liu S, Ai F, Zhang D, Xiao Z, Nie X, et al. miR-107 promotes proliferation and inhibits apoptosis of colon cancer cells by targeting prostate apoptosis response-4 (Par4). Oncol Res. 2017;25:967\u201374.","journal-title":"Oncol Res"},{"key":"1042_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s13402-023-00806-9","volume":"46","author":"R Bhattacharjee","year":"2023","unstructured":"Bhattacharjee R, Prabhakar N, Kumar L, Bhattacharjee A, Kar S, Malik S, et al. Crosstalk between long noncoding RNA and microRNA in cancer. Cell Oncol. 2023;46:885\u2013908.","journal-title":"Cell Oncol"},{"key":"1042_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/ijms.84072","volume":"21","author":"M Luo","year":"2024","unstructured":"Luo M, Lei R, Zhao Q, Shen Y, He Z, Xu J. LINC00662 promotes melanoma progression by competitively binding miR-107 and activating the beta-catenin signaling pathway. Int J Med Sci. 2024;21:265\u201376.","journal-title":"Int J Med Sci"},{"key":"1042_CR33","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3892\/ol.2020.12168","volume":"20","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Chen Z. lncRNA UASR1 sponges miR-107 in colorectal cancer to upregulate oncogenic CDK8 and promote cell proliferation. Oncol Lett. 2020;20:305.","journal-title":"Oncol Lett"},{"key":"1042_CR34","doi-asserted-by":"crossref","unstructured":"Menon A, Abd-Aziz N, Khalid K, Poh CL, Naidu R. miRNA: a promising therapeutic target in cancer. Int J Mol Sci. 2022;23:11502.","DOI":"10.3390\/ijms231911502"},{"key":"1042_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114697","volume":"451","author":"C Ke","year":"2025","unstructured":"Ke C, Wang P, Chen B, Cheng X, Zhang X, Xia R, et al. Upregulation of Linc00960 promotes colorectal cancer cell proliferation by regulating hsa-miR-107\/CDK6 axis. Exp Cell Res. 2025;451:114697.","journal-title":"Exp Cell Res"},{"key":"1042_CR36","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.3390\/cells13171483","volume":"13","author":"E Siedlecki","year":"2024","unstructured":"Siedlecki E, Remiszewski P, Stec R. The role of circHIPK3 in tumorigenesis and its potential as a biomarker in lung cancer. Cells. 2024;13:1483.","journal-title":"Cells"},{"key":"1042_CR37","doi-asserted-by":"crossref","unstructured":"Braga EA, Fridman MV, Burdennyy AM, Loginov VI, Dmitriev AA, Pronina IV, et al. Various LncRNA mechanisms in gene regulation involving miRNAs or RNA-binding proteins in non-small-cell lung cancer: main signaling pathways and networks. Int J Mol Sci. 2023;24:13617.","DOI":"10.3390\/ijms241713617"},{"key":"1042_CR38","doi-asserted-by":"crossref","unstructured":"Puente-Rivera J, De la Rosa Perez DA, Olvera SIN, Figueroa-Angulo EE, Saucedo JGC, Hernandez-Leon O, et al. The circulating miR-107 as a potential biomarker up-regulated in castration-resistant prostate cancer. Noncoding RNA. 2024;10:47.","DOI":"10.3390\/ncrna10050047"},{"key":"1042_CR39","first-page":"2342","volume":"13","author":"J Zhang","year":"2020","unstructured":"Zhang J, Sun J, Liu J, Gu D, Shi X. Correlation between microRNA-107 expression level and prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2020;13:2342\u20137.","journal-title":"Int J Clin Exp Pathol"},{"key":"1042_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.31557\/APJCP.2020.21.2.391","volume":"21","author":"JD Pinho","year":"2020","unstructured":"Pinho JD, Silva GEB, Teixeira Junior AAL, Belfort MRC, Mendes JM, Cunha IWD, et al. MIR-107, MIR-223-3P and MIR-21-5P reveals potential biomarkers in penile cancer. Asian Pac J Cancer Prev. 2020;21:391\u20137.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1042_CR41","doi-asserted-by":"crossref","unstructured":"Cao T, Lu Y, Wang Q, Qin H, Li H, Guo H, et al. A CGA\/EGFR\/GATA2 positive feedback circuit confers chemoresistance in gastric cancer. J Clin Investig. 2022;132:e154074.","DOI":"10.1172\/JCI154074"},{"key":"1042_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107522","volume":"300","author":"P Wang","year":"2024","unstructured":"Wang P, Zhou Y, Wang J, Zhou Y, Zhang X, Liu Y, et al. miR-107 reverses the multidrug resistance of gastric cancer by targeting the CGA\/EGFR\/GATA2 positive feedback circuit. J Biol Chem. 2024;300:107522.","journal-title":"J Biol Chem"},{"key":"1042_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.4103\/jomfp.jomfp_349_22","volume":"27","author":"P Thomas","year":"2023","unstructured":"Thomas P, Preethi KA, Selvakumar SC, Ramani P, Sekar D. Relevance of micro-RNAs and their targets as a diagnostic and prognostic marker in oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2023;27:364\u201373.","journal-title":"J Oral Maxillofac Pathol"},{"key":"1042_CR44","doi-asserted-by":"publisher","first-page":"256","DOI":"10.23736\/S2724-6329.23.04835-0","volume":"73","author":"MS Varshan","year":"2024","unstructured":"Varshan MS, Selvakumar SC, Preethi KA, Murthykumar K, Ganapathy DM, Sekar D. MicroRNA-34a-3p and its target tumor necrosis factor-alpha in the regulation of South Indian oral squamous cell carcinoma population. Minerva Dent Oral Sci. 2024;73:256\u201363.","journal-title":"Minerva Dent Oral Sci"},{"key":"1042_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2025.106403","volume":"180","author":"KP Ameya","year":"2025","unstructured":"Ameya KP, Usman PPA, Sekar D. OIP5-AS1 expression profiles in different stages of oral squamous cell carcinoma. Arch Oral Biol. 2025;180:106403.","journal-title":"Arch Oral Biol"},{"key":"1042_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06137-8","volume":"7","author":"T Imamura","year":"2017","unstructured":"Imamura T, Komatsu S, Ichikawa D, Miyamae M, Okajima W, Ohashi T, et al. Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer. Sci Rep. 2017;7:5708.","journal-title":"Sci Rep"},{"key":"1042_CR47","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/wrna.1229","volume":"5","author":"MY Shah","year":"2014","unstructured":"Shah MY, Calin GA. MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA. 2014;5:537\u201348.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"1042_CR48","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.3390\/ijms25031469","volume":"25","author":"AA Seyhan","year":"2024","unstructured":"Seyhan AA. Trials and tribulations of MicroRNA therapeutics. Int J Mol Sci. 2024;25:1469.","journal-title":"Int J Mol Sci"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01042-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01042-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:49:46Z","timestamp":1786448986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-026-01042-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1042"],"URL":"https:\/\/doi.org\/10.1038\/s41417-026-01042-7","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}